Sacubitril/valsartan (ARNI therapy) improves heart failure outcomes by boosting natriuretic peptide levels through neprilysin inhibition, enhancing their cardioprotective effects.
3 peptides boostedARNI therapy increases BNP, ANP, and CNP by preventing their enzymatic breakdown
What the researchers found
ARNI therapy boosts BNP, ANP, and CNP levels through neprilysin inhibition, explaining its superior outcomes in HFrEF through enhanced natriuretic peptide-mediated cardioprotection.
Why it matters
Understanding how ARNI therapy works through natriuretic peptides helps clinicians optimize treatment and researchers develop next-generation heart failure therapies.
The numbers in context
BNP ↑, NT-proBNP ↓, ANP ↑, CNP unchanged; both BNP/NT-proBNP retain prognostic accuracy; correlate with echo improvement
How the study worked
Review of natriuretic peptide biology, neprilysin pharmacology, and ARNI clinical trial data.
Who was studied
Heart failure with reduced ejection fraction patients on ARNI therapy
What this study cannot tell us
Review focused on natriuretic peptides — ARNI also affects other neprilysin substrates which may contribute to its effects.
How to read the evidence
Review of established clinical trial evidence and natriuretic peptide biology. Strong evidence base.
When this study was published
Published in 2020. ARNI therapy has become standard care for HFrEF.
The bigger picture
Natriuretic peptides are the body's natural heart-protective system. ARNI therapy works by preventing their degradation, representing a fundamentally different approach to heart failure treatment.
Questions still open
- Which natriuretic peptide contributes most to ARNI's clinical benefits?
- Can natriuretic peptide levels predict ARNI treatment response?
- Would natriuretic peptide analogs work in heart failure?
Common questions
What are natriuretic peptides?
How does sacubitril/valsartan help the heart?
Read the original research
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Current heart failure reports, 17(3), 67-76
Citation
Vasquez, Nestor; Carter, Spencer; Grodin, Justin L. (2020). Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.. Current heart failure reports, 17(3), 67-76. https://doi.org/10.1007/s11897-020-00458-y